Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patentl and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information upless contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

equired to respond to a collection of information unless it contains a valid OMB control number					
Complete if Known					
Application Number	10/551,998				
Filing Date	October 5, 2006				
First Named Inventor	Kai SCHIEMANN, et al.				
Group Art Unit	1626				
Examiner Name	Yong Liang Chu				
Attorney Docket Number	MERCK-3073				

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Documer	nt Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
/Y.C./	A1	2004/0034083		Stephenson et al.	02-19-2004	
	A2	2002/0091116		Zhu et al.	07-2002	
	АЗ	2007/0010531		Schadt et al.	01-2007	
	A4	2006/0264419		Schiemann et al.	11-2006	
	A5	2006/0276650		Schadt et al.	12-7-2006	
	A6	4,258,047		Gante et al.	03-24-1981	
	A7	3,926,999		Poetsch	12-16-1975	
	A8 2007/0093492		Jiaang et al.	04-2007		
	A9	2001/0044445		Bamaung et al.	11-2001	
	A10	7,067,507		Pulley et al.	06-2006	
	A11	4,631,343		Beck, James R.	12-1986	
	A12	2005/023979		Gaster et al.	10-27-2005	
W	A13	6,100,259		Xiang et al.	08-08-2000	
/Y.C./	A14	6,407,238		Baron et al.	06-18-2002	

FOREIGN PATENT DOCUMENTS									
Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant					
	miner ials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T*
/Y.	.C./	B1	wo	03088958		Maziasz Timothy J.	10-30-2003		A1
		B2	wo	0132626		Gaster Laramie Mary	05-10-2001		A12
		Вз	wo	9831227		Schiemann et al.	07-1998		A1:
		B4	wo	03031435		Schiemann et al.	04-2003		
		B5	DE	2906252		Merck Patent GmbH	08-28-1980		A6
V	/_	B6	DE	2201889		Merck Patent Gmbh	07-19-1973		A7
N	C/	B7	wo	0132627		Baron et al.	05-10-2001		A14

Examiner Signature /Yong Chu/	Date Considered	03/06/2009
----------------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique challon designation number. ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document by the two-test code (WPO Sandard ST3). ² For Jupainese patent documents, the includation of the year of the reign of the Emporer mate patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated on the document under WPO Sandard ST. ³ following the special symbols as indicated sy

Buden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time vary are required to complete his form should be sent to the Chief Information Chiefe, U.S. Patent and Trademark. Office. Washington, D.O. 2024: D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. 50x 1450. Alexandrial, Val 22313-1450.

Examiner

Nona Chul

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 10/551,998 INFORMATION DISCLOSURE Filing Date October 5, 2006 STATEMENT BY APPLICANT First Named Inventor Kai SCHIEMANN, et al. Group Art Unit (use as many sheets as necessary) Examiner Name Yong Liang Chu Sheet Attorney Docket Number MERCK-3073

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, [journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
/Y.C./	C1	Ross et al., Expert Opinion on Therapeutic Patents, 2003, 13(10), 1491-99.	
/Y.C./		DATABASE BEILSTEIN "ONLINE! BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; JUNE 27, 1988, XP002283830.	
Y.C./	СЗ	Vippagunta et al., Advanced Drug Delivery Reviews, 2001, 48, 3-26.	
/Y.C./	C4	Premenstrual syndrome-Womens health and Medical Information in Medicinenet.com", http://www.medicinenet.com/premenstrual_syndrome/page5.htm, accessed September 19, 2007.	
/Y.C./	C5	Amyotrophic Lateral sclerosis information page: National Institute of Neurological Disorders and Stroke (NINDS)*, http://www.ninds.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm, accessed September 19, 2007.	
/Y.C./	C6	Obsessive-compulsive behaviors and disorders: symptoms, treatment, and support", http://www.helpguide.org/mental/obsessive_compulsive_disorder_ocd.htm, accessed September 19, 2007.	
/Y.C./	C7	Journal of Clinical Psychiatry, 1999, 60, 1-8.	
/Y.C./	C8	Crow, S. Expert Opinion on Investigational Drugs, 1997, 6(4), 427-36.	
/Y.C./	C9	Non Final Rejection dated May 7, 2007 - U.S. application no. 10/552,064 filed October 5, 2005 (Publication No. US-2007-0010531-A1).	
Name and Associated a	C10	Non Final Rejection dated September 29, 2007 - U.S. application no. 10/552,064 filed October 5, 2005 (Publication No. US-2007-0010531-A1).	
	C11	Final Rejection dated July 9, 2008 - U.S. application no. 10/552,064 filed October 5, 2005 (Publication No. US-2007-0010531-A1).	
		Non Final Rejection dated August 25, 2008 - U.S. application no. 10/552,065 filed October 5, 2005 (Publication No. US-2006-0264419-A1).	
$\sqrt{}$	C13	Non Final Rejection dated January 22, 2008 - U.S. application no. 10/551,905 filed October 5, 2005 (Publication No. US-2006-0276650-A1).	
/Y.C./	C14	Final Rejection dated August 8, 2008 - U.S. application no. 10/551,905 filed October 5, 2005 (Publication No. US-2006-0276650-A1).	

	Signature	7. Ging 6.10	Considered	/Yong Chu/		
"EVAMINED Total if reference considered whether or not citation is in confermance with MDED 600. Draw line through citation if not in						

Date

and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark.

Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.